LipoCURE

At a glance

Established in 2009 by Prof. Yechezkel Barenholtz, Lipocure is a preclinical stage company developing novel liposomal drug candidates for post-surgical pain. LC400 is a novel liposomal hydrogel formulation of Bupivacaine for post-surgical pain. Lipocure’s drug candidates are based on liposomal chemistry that is characterized by the ability to improve pharmacological and pharmacokinetic profiles of known drugs as demonstrated in a large set of robust and comparative assessment system.

Company Highlights

Lipocure leverages on the vast experience and proven success of Prof. Barenholtz, a world leader in Liposome chemistry and therapeutics, including Doxil® that was then developed and commercialized by Johnson & Johnson.
As a platform technology, Lipocure has endless potential in its applications and the current pipeline represents products with very large commercial potential.